• LAST PRICE
    1.2200
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.0000/ 1
  • Ask / Lots
    1.2700/ 1
  • Open / Previous Close
    0.0000 / 1.2200
  • Day Range
    ---
  • 52 Week Range
    Low 0.6801
    High 2.5700
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 1.24
TimeVolumeCYTH
09:32 ET2081.21
09:36 ET1001.27
09:50 ET15521.24
10:01 ET16861.23
10:26 ET3001.2208
10:30 ET13991.2203
10:32 ET4751.27
11:15 ET10001.2121
11:18 ET5001.23
11:56 ET13651.24
12:05 ET17491.2
12:21 ET26141.18
12:32 ET9471.1876
12:38 ET5001.19
12:43 ET20001.1899
12:52 ET5151.1701
12:59 ET48511.18
01:06 ET111001.14
01:08 ET22541.14
01:10 ET11001.1228
01:14 ET75811.16
01:30 ET2451.185
01:33 ET49181.14
01:35 ET1001.13
01:48 ET105591.16
01:50 ET10001.21
02:02 ET1001.13
03:05 ET2001.225
03:09 ET12761.2059
03:14 ET4571.214
03:57 ET5001.2099
03:59 ET2961.22
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCYTH
Cyclo Therapeutics Inc
35.0M
-0.9x
---
United StatesVYNE
Vyne Therapeutics Inc
34.1M
-0.4x
---
United StatesAPM
Aptorum Group Ltd
39.6M
-2.1x
---
United StatesACST
Acasti Pharma Inc
31.5M
-0.7x
---
United StatesLEXX
Lexaria Bioscience Corp
29.8M
-3.4x
---
United StatesBGXX
Bright Green Corp
41.9M
-4.1x
---
As of 2024-04-17

Company Information

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing transformative therapies for rare and neurological diseases with limited treatment options. The Company’s Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin. It is an orphan drug designated product in the United States and Europe, and is the subject of four formal clinical trials for Niemann-Pick Disease Type C (NPC) disease. NPC is a rare and fatal autosomal recessive genetic disease resulting in disrupted cholesterol metabolism that impacts the brain, lungs, liver, spleen, and other organs. The Company is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842).

Contact Information

Headquarters
6714 Nw 16Th Street,, Suite BGAINESVILLE, FL, United States 32653
Phone
386-418-8060
Fax
---

Executives

Independent Chairman of the Board
Markus Sieger
Chief Executive Officer, Director
N. Scott Fine
Independent Vice Chairman of the Board
F. Patrick Ostronic
Founder, Independent Director
C.E. Strattan
Chief Financial Officer, Secretary
Joshua Fine

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$35.0M
Revenue (TTM)
$1.1M
Shares Outstanding
28.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.12
EPS
$-1.33
Book Value
$0.17
P/E Ratio
-0.9x
Price/Sales (TTM)
32.5
Price/Cash Flow (TTM)
---
Operating Margin
-1,862.68%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.